AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9874860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5 mg
Number of subjects: 10
Study 9874860 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 10
Study 7978146 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% plain
Number of subjects: 30
Study 7978146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain and triamcinolone acetonide 40 mg
Number of subjects: 30
Study 2656626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 68
Study 2656626 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 68
Study 4376998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intravenous cyclophosphamide
Number of subjects: 24
Study 4376998 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral Melphalan therapy
Number of subjects: 24
Study 10910243 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 27
Study 10910243 — intervention group
Group type: COMPARATOR
Intervention: No stoma
Number of subjects: 27
Study 31221354 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 15
Study 29039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 153
Study 29039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 153
Study 29039073 — intervention group
Group type: COMPARATOR
Intervention: Control (standard antiemetic treatment)
Number of subjects: 153
Study 26585957 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly messages comparing statin adherence to other participants (comparison)
Number of subjects: 401
Study 26585957 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly summaries of statin adherence (summary)
Number of subjects: 401
Study 26585957 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily reports to Medication Adherence Partner (MAP)
Number of subjects: 401
Study 26585957 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly reports to MAP
Number of subjects: 401
Study 26585957 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports to MAP only if dose was missed
Number of subjects: 401
Study 26585957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 401
Study 24469527 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy for auditory verbal hallucinations (AVHs)
Number of subjects: 41
Study 22947847 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening product used twice daily for 3 weeks
Number of subjects: 62
Study 22947847 — intervention group
Group type: COMPARATOR
Intervention: No whitening products
Number of subjects: 62
Study 21187549 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transpedicular vertebroplasty using calcium phosphate cement (CPC)
Number of subjects: 36
Study 21187549 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 36
Study 18166121 — intervention group
Group type: EXPERIMENTAL
Intervention: 024 essential oil
Number of subjects: 43
Study 18166121 — intervention group
Group type: COMPARATOR
Intervention: Sham oil
Number of subjects: 43
Study 16320801 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (300 mg, containing 1.3% allicin, twice daily)
Number of subjects: 70
Study 16320801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets)
Number of subjects: 70
Study 12030110 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-α2a 3.0 μ/m2 s.c. Monday, Wednesday, and Friday weeks 1-8; interleukin-2 11 μ/m2 s.c. Tuesday, Thursday and Saturday of weeks 1-4; cis-retinoic acid 1 mg/kg po daily weeks 1-8; 5-fluorouracil 750 mg/m2 IV weekly during weeks 5-8
Number of subjects: 58
Study 9814639 — intervention group
Group type: EXPERIMENTAL
Intervention: fampridine-SR 12.5 and 17.5 mg b.i.d. over a 2-week treatment period
Number of subjects: 26
Study 9814639 — intervention group
Group type: EXPERIMENTAL
Intervention: fampridine-SR
Number of subjects: 26
Study 9814639 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 7808737 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart operated patients
Number of subjects: 64
Study 7808737 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 64
Study 2510608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamin 9 glucose
Number of subjects: 14
Study 2510608 — intervention group
Group type: COMPARATOR
Intervention: Vaminolact
Number of subjects: 14
Study 2510608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 14
Study 1058212 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment by grinding
Number of subjects: 29
Study 1058212 — intervention group
Group type: COMPARATOR
Intervention: Control (no occlusal adjustment)
Number of subjects: 29
Study 31711085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft group (bone graft placed between the implant and inferior alveolar nerve)
Number of subjects: 82
Study 31711085 — intervention group
Group type: COMPARATOR
Intervention: Control group (implants placed in direct contact with the inferior alveolar nerve)
Number of subjects: 82
Study 31711085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 28585585 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone Gel (0.05%)
Number of subjects: 120
Study 28585585 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine Gel (4.0%)
Number of subjects: 120
Study 25340384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 25
Study 25340384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22305297 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (13.3mg/kg PO q 8h) and azithromycin (10-12.5mg/kg PO q 24h)
Number of subjects: 12
Study 22305297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19237189 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio bonded with Solobond
Number of subjects: 30
Study 19237189 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram bonded with Syntac
Number of subjects: 30
Study 17508991 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of around 0.03%
Number of subjects: 16
Study 17508991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 16
Study 15485755 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus nurse care management intervention (INT)
Number of subjects: 150
Study 15485755 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care only (UC)
Number of subjects: 150
Study 11242726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hytac
Number of subjects: 0
Study 11242726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 0
Study 11242726 — intervention group
Group type: COMPARATOR
Intervention: Amalgam or other tooth-colored materials
Number of subjects: 0
Study 9402170 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (< 35 years)
Number of subjects: 1283
Study 9402170 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥ 70 years)
Number of subjects: 1283
Study 9402170 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged patients (35-69 years)
Number of subjects: 1283
Study 9402170 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 1283
Study 9402170 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 1283
Study 9402170 — intervention group
Group type: EXPERIMENTAL
Intervention: All age groups
Number of subjects: 1283
Study 8430921 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (two dosage levels)
Number of subjects: 14
Study 2441648 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 0.4 mg/kg/day
Number of subjects: 53
Study 2441648 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 0.8 mg/kg/day
Number of subjects: 53
Study 2441648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30350717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin injection (Jetrea®)
Number of subjects: 0
Study 30350717 — intervention group
Group type: COMPARATOR
Intervention: Control (no ocriplasmin)
Number of subjects: 0
Study 28481690 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R II
Number of subjects: 752
Study 28481690 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT
Number of subjects: 752
Study 28481690 — intervention group
Group type: COMPARATOR
Intervention: M-M-R II and MMR-RIT
Number of subjects: 752
Study 26181705 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week pharmacotherapy-based algorithm treatment
Number of subjects: 100
Study 26181705 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study 23953784 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 65
Study 23953784 — intervention group
Group type: COMPARATOR
Intervention: Epidural (EPI)
Number of subjects: 65
Study 19825842 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive community-based program
Number of subjects: 2180000
Study 19825842 — intervention group
Group type: COMPARATOR
Intervention: Reference community
Number of subjects: 2180000
Study 18573617 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral continuing care adherence intervention (CPR) involving contracting, prompting, and reinforcing attendance
Number of subjects: 150
Study 18573617 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (STX)
Number of subjects: 150
Study 17213002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered at 3, 7, and 11 pm (total daily dose, 1200 mg)
Number of subjects: 30
Study 17213002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14586357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (2 sprays of 400 mcg)
Number of subjects: 99
Study 14586357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 sprays)
Number of subjects: 99
Study 10758957 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization with CO2 laser (TMR) in addition to optimal medical treatment (MT)
Number of subjects: 100
Study 10758957 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment (MT)
Number of subjects: 100
Study 9066360 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and magnetic resonance spectroscopic imaging
Number of subjects: 28
Study 9066360 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopic imaging
Number of subjects: 28
Study 9066360 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of averaged metabolite and T2-weighted lesion probability images
Number of subjects: 28
Study 8320424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day) + calcium (500 mg/day)
Number of subjects: 32
Study 8320424 — intervention group
Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 32
Study 3549990 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (70 mg/m2, slow push, every 3 weeks for seven courses, maximum 550 mg/m2)
Number of subjects: 47
Study 3549990 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 47
Study 28497534 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) - 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 12 months
Number of subjects: 65
Study 28497534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TRT)
Number of subjects: 65
Study 27557654 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-fat cheese (REG)
Number of subjects: 164
Study 27557654 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat cheese (RED)
Number of subjects: 164
Study 27557654 — intervention group
Group type: COMPARATOR
Intervention: No-cheese, carbohydrate control (CHO)
Number of subjects: 164
Study 27557654 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (REG, RED, CHO)
Number of subjects: 164
Study 25539989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention involving a 2-day GP workshop and patient education sessions scheduled at 1, 4, 7, 10, 13, and 19 months.
Number of subjects: 400
Study 25539989 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without the intervention).
Number of subjects: 400
Study 22460421 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 0
Study 22460421 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 20403351 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirab (Vero cell based rabies vaccine)
Number of subjects: 561
Study 20403351 — intervention group
Group type: COMPARATOR
Intervention: Verorab (reference vaccine)
Number of subjects: 561
Study 18689364 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet S (24 g soy protein and 70-80 mg isoflavones)
Number of subjects: 91
Study 18689364 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet SD (12 g soy protein, 12 g dairy protein, and 70-80 mg isoflavones)
Number of subjects: 91
Study 18689364 — intervention group
Group type: COMPARATOR
Intervention: Diet D (24 g dairy protein without isoflavones)
Number of subjects: 91
Study 15844839 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiong‐gui‐tiao‐xue‐yin (Kyuki‐chouketsu‐in) at a dose of 6.0 g/day
Number of subjects: 268
Study 15844839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Xiong‐gui‐tiao‐xue‐yin)
Number of subjects: 268
Study 11394426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (group O)
Number of subjects: 200
Study 11394426 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg (group D)
Number of subjects: 200
Study 11394426 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg (group M)
Number of subjects: 200
Study 9891192 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal prochlorperazine
Number of subjects: 0
Study 9891192 — intervention group
Group type: COMPARATOR
Intervention: Oral prochlorperazine
Number of subjects: 0
Study 7981800 — intervention group
Group type: EXPERIMENTAL
Intervention: First tarsometatarsal reorientation arthrodesis
Number of subjects: 0
Study 2598991 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional formulation of Carbamazepine (CBZ)
Number of subjects: 6
Study 2598991 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of Carbamazepine (CBZ)
Number of subjects: 6
Study 2598991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 19375095 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education cohort
Number of subjects: 206
Study 19375095 — intervention group
Group type: COMPARATOR
Intervention: Bolus cohort
Number of subjects: 206
Study 371974 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,3-dihydroxybenzoic acid (2,3-DHB) at a dose of 25 mg/kg four times per day
Number of subjects: 15
Study 371974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol)
Number of subjects: 15
Study 371974 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,3-dihydroxybenzoic acid (2,3-DHB)
Number of subjects: 15
Study 30844984 — intervention group
Group type: EXPERIMENTAL
Intervention: In-season weightlifting training (conducted biweekly for 12 weeks)
Number of subjects: 22
Study 28704936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (berberine 200 mg, monacolin K 3 mg, chitosan 10 mg, coenzyme Q 10 mg)
Number of subjects: 39
Study 28704936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26490344 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training on a bicycle ergometer for 15 minutes, 3 times per week for 6 weeks
Number of subjects: 60
Study 26490344 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercises for 30 minutes, 3 times per week for 6 weeks
Number of subjects: 60
Study 26490344 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (aerobic and isotonic exercises)
Number of subjects: 60
Study 24500106 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 193
Study 24500106 — intervention group
Group type: COMPARATOR
Intervention: Workbook intervention
Number of subjects: 193
Study 24500106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 193
Study 21723044 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Dressing (NPD) at 80 mm Hg for four days
Number of subjects: 30
Study 21723044 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing (Vaseline gauze and cotton pads)
Number of subjects: 30
Study 19301720 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once a day for five days
Number of subjects: 40
Study 19301720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17518967 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 681
Study 17518967 — intervention group
Group type: COMPARATOR
Intervention: Traditional Amalgam (TA)
Number of subjects: 681
Study 15195867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once daily
Number of subjects: 45
Study 15195867 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 45
Study 11270008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 8
Study 11270008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 8
Study 11270008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9921943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed group (povidone-iodine gel applied to subcutaneous tissue)
Number of subjects: 59
Study 9921943 — intervention group
Group type: COMPARATOR
Intervention: Open group (usual treatment)
Number of subjects: 59
Study 8042237 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU vitamin E orally per day for 2 months
Number of subjects: 20
Study 8042237 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E (control)
Number of subjects: 20
Study 3281487 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (200 mg daily)
Number of subjects: 170
Study 3281487 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (300 mg weekly)
Number of subjects: 170
Study 30443664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of corticosteroid injections and strength training/stretching (n=29)
Number of subjects: 90
Study 30443664 — intervention group
Group type: COMPARATOR
Intervention: Strength training and stretching (n=30)
Number of subjects: 90
Study 30443664 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injections (n=31)
Number of subjects: 90
Study 28160288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour cryotherapy
Number of subjects: 0
Study 28160288 — intervention group
Group type: COMPARATOR
Intervention: 6-hour cryotherapy
Number of subjects: 0
Study 28160288 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan exposure
Number of subjects: 0
Study 26700861 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2a therapy for 48 weeks
Number of subjects: 22
Study 24340290 — intervention group
Group type: EXPERIMENTAL
Intervention: BBTI treatment
Number of subjects: 39
Study 20943352 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study 19918858 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 374
Study 19918858 — intervention group
Group type: COMPARATOR
Intervention: Hospital follow-up
Number of subjects: 374
Study 17022791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/day
Number of subjects: 244
Study 17022791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 17022791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/day
Number of subjects: 244
Study 17022791 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 150 mg/day
Number of subjects: 244
Study 12723838 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard def-t criteria
Number of subjects: 0
Study 12723838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyvad's new caries diagnostic criteria
Number of subjects: 0
Study 11445758 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained women (ET)
Number of subjects: 14
Study 11445758 — intervention group
Group type: COMPARATOR
Intervention: Moderately active women (MA)
Number of subjects: 14
Study 9926802 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable insulin pump
Number of subjects: 51
Study 9926802 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injections
Number of subjects: 51
Study 8067597 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine, 2 mg bid
Number of subjects: 199
Study 8067597 — intervention group
Group type: COMPARATOR
Intervention: Clemastine fumarate, 1.34 mg bid
Number of subjects: 199
Study 8067597 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid
Number of subjects: 199
Study 2658502 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nursing homes
Number of subjects: 0
Study 30639384 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with tocotrienol
Number of subjects: 23
Study 28934950 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 0
Study 28934950 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture treatment
Number of subjects: 0
Study 25797560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus daily navitoclax for 12 weeks (arm B)
Number of subjects: 118
Study 25797560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus daily navitoclax until disease progression or unacceptable toxicity (arm C)
Number of subjects: 118
Study 25797560 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (arm A)
Number of subjects: 118
Study 22952365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried fermentation biomass (DFB)
Number of subjects: 92